Kite, Humanigen to evaluate Yescarta, Lenzilumab combo in relapsed/refractory DLBCL

This article was originally published here

The objective of this study is to determine the effect of lenzilumab on the safety of Yescarta. Kite will act as the sponsor of this study and will

The post Kite, Humanigen to evaluate Yescarta, Lenzilumab combo in relapsed/refractory DLBCL appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply